Qiuxiang Ou

2.9k total citations · 1 hit paper
112 papers, 1.8k citations indexed

About

Qiuxiang Ou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Qiuxiang Ou has authored 112 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 57 papers in Cancer Research. Recurrent topics in Qiuxiang Ou's work include Cancer Genomics and Diagnostics (52 papers), Lung Cancer Treatments and Mutations (43 papers) and Lung Cancer Research Studies (19 papers). Qiuxiang Ou is often cited by papers focused on Cancer Genomics and Diagnostics (52 papers), Lung Cancer Treatments and Mutations (43 papers) and Lung Cancer Research Studies (19 papers). Qiuxiang Ou collaborates with scholars based in China, United States and Canada. Qiuxiang Ou's co-authors include Xue Wu, Kirst King‐Jones, Yang Shao, Hua Bao, Xiaonan Wang, Xiaoling Tong, Caicun Zhou, Yi Xiang, Nong Yang and Tao Jiang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Qiuxiang Ou

97 papers receiving 1.8k citations

Hit Papers

Investigating Novel Resistance Mechanisms to Third-Genera... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
    2018 390 citations Zhe Yang, Nong Yang et al. Clinical Cancer Research profile →

Peers

Qiuxiang Ou
Rainer Lehtonen Finland
Jonathan D. Wasserman Canada
Arja ter Elst Netherlands
Milada Zemanová Czechia
Simone M. Rowley Australia
Xiaochun Ni China
E Shyam P Reddy United States
Gibbes R. Johnson United States
Michael G. Gartside Australia
Dido Lenze Germany
Rainer Lehtonen Finland
Qiuxiang Ou
Citations per year, relative to Qiuxiang Ou Qiuxiang Ou (= 1×) peers Rainer Lehtonen

Countries citing papers authored by Qiuxiang Ou

Since Specialization
Citations

This map shows the geographic impact of Qiuxiang Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiuxiang Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiuxiang Ou more than expected).

Fields of papers citing papers by Qiuxiang Ou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiuxiang Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiuxiang Ou. The network helps show where Qiuxiang Ou may publish in the future.

Co-authorship network of co-authors of Qiuxiang Ou

This figure shows the co-authorship network connecting the top 25 collaborators of Qiuxiang Ou. A scholar is included among the top collaborators of Qiuxiang Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiuxiang Ou. Qiuxiang Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ding, Ning, Jiahui Chen, Xiaotian Zhao, et al.. (2025). Multi-omics approach reveals gene co-alterations and survival benefit in ovarian cancer patients under platinum-based adjuvant therapy. Genes & Diseases. 12(6). 101628–101628.
2.
Feng, Xiaoli, Fengwei Tan, Qi Xue, et al.. (2025). Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I–III micropapillary lung adenocarcinoma. The Journal of Pathology. 266(2). 204–216. 1 indexed citations
3.
Ding, Bo, Tingyan Liu, Hairong Bao, et al.. (2024). Anlotinib treatment for rapidly progressing pediatric embryonal rhabdomyosarcoma in the maxillary gingiva: a case report. Diagnostic Pathology. 19(1). 135–135.
4.
Du, Yu, Ming Sun, Shanshan Qi, et al.. (2024). Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6524–6524. 1 indexed citations
5.
Kang, Xiaozheng, Liyan Xue, Xiaotian Zhao, et al.. (2024). Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial. Clinical Cancer Research. 30(22). 5061–5072. 4 indexed citations
6.
Li, Yang, Mengchen Zhu, Xiaotian Zhao, et al.. (2024). The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. Future Oncology. 20(38). 3107–3117. 1 indexed citations
7.
Sun, Yi, et al.. (2024). Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis. The Journal of Pathology Clinical Research. 10(3). 1 indexed citations
8.
9.
Liu, Jun, Xiao‐Dan Weng, Jiaping Zhao, et al.. (2023). Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution. Frontiers in Oncology. 13. 1150098–1150098. 4 indexed citations
10.
Yao, Yu, Huaping Yang, Bo Zhu, et al.. (2023). Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Respiratory Research. 24(1). 28–28. 10 indexed citations
11.
Pu, Jun, Ruoying Yu, Qiuxiang Ou, et al.. (2023). Pan‐cancer molecular analysis of EGFR large fragment deletion in the Asian population. Cancer Medicine. 12(7). 8083–8088. 2 indexed citations
12.
Zhao, Xiaotian, Jingwen Liu, Yang Xu, et al.. (2022). Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer. Molecular Oncology. 16(20). 3689–3702. 5 indexed citations
13.
Yu, Ruoying, Qiuxiang Ou, Hua Bao, et al.. (2022). Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population. Cancer Medicine. 12(5). 6009–6015. 3 indexed citations
14.
Li, Chong, Sisi Liu, Wanxiangfu Tang, et al.. (2022). Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. Journal of Oncology. 2022. 1–10. 3 indexed citations
15.
Chen, Cunte, Si‐Yang Maggie Liu, Yedan Chen, et al.. (2022). Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. Cancer Immunology Immunotherapy. 72(5). 1261–1272. 1 indexed citations
16.
Wang, Hui, Zhiwei Li, Qiuxiang Ou, et al.. (2022). NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Medicine. 11(13). 2541–2549. 40 indexed citations
17.
Li, Dan, et al.. (2021). Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors. Cancer Communications. 41(2). 183–186. 3 indexed citations
18.
Li, Binghao, Hao Qu, Jing Zhang, et al.. (2021). Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions. npj Precision Oncology. 5(1). 81–81. 17 indexed citations
19.
Han, Yuchen, Li Pan, Jianying Zhang, et al.. (2020). Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing. Molecular Oncology. 14(11). 2787–2795. 26 indexed citations
20.
Yang, Zhe, Nong Yang, Qiuxiang Ou, et al.. (2018). Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. 24(13). 3097–3107. 390 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rainer Lehtonen Breakdown of academic impact, for papers by Jonathan D. Wasserman Breakdown of academic impact, for papers by Arja ter Elst Breakdown of academic impact, for papers by Milada Zemanová Breakdown of academic impact, for papers by Simone M. Rowley Breakdown of academic impact, for papers by Xiaochun Ni Breakdown of academic impact, for papers by E Shyam P Reddy Breakdown of academic impact, for papers by Gibbes R. Johnson Breakdown of academic impact, for papers by Michael G. Gartside Breakdown of academic impact, for papers by Dido Lenze
Rankless by CCL
2026